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Background
Willingness to participate (WTP) in prophylactic HIV vac-
cine trials have been investigated amongst individuals at
high risk for HIV and not in the actual HIV vaccine trial
itself. We assessed the willingness and barriers to partici-
pation in an actual preventive HIV vaccine trial.
Methods
General population in Bangkok inquired about the HIV
vaccine trial. Several questionnaires on HIV vaccine trial
knowledge were completed during the recruitment proc-
ess of phase I/IIa trial of DNA/Fowlpox vaccine. Self
administered questionnaires on sexual HIV risk behavior,
reasons and concerns to participate were completed at the
end of the trial by participants and non-participants.
Results
From 131 participants who inquired, the median age was
34 years (IQR: 27 – 46), 73% were male and 30% had at
least a bachelor's degree and 11% were screened for the
trial. Only 34% completed HIV vaccine knowledge ques-
tionnaires, the median score was not significantly differ-
ent between those who came to screen and those who did
not (median score was 7 (IQR 6 – 8) and 6 (IQR 5 – 8)
respectively; p = 0.44). Baseline characteristics and
method to recruit participants were not different between
two groups. Of the 43% who completed self-administered
questionnaires, those who were, male gender were more
willing (p = 0.038; OR = 6.29, 95% CI = 0.75–52.68) by
univariate analysis. Age and education were not associ-
ated with WTP. Knowing someone infected with HIV sig-
nificantly decreased WTP (p = 0.04; OR = 0.23, 95% CI =
0.05–1.01). The most common reasons volunteers
declined to participate were concerns that their family
would not want them to join and being not sure about the
safety of the vaccine.
Conclusion
The low rate of actual WTP is common to HIV vaccine tri-
als. Community education on the importance and safety
of the vaccine is needed.
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